Evidence map›Paper›PMID 29853524›Full record

ArticleBlood advances2018

In vivo RNAi screening identifies

Eleanor R C Fiedler, Arjun Bhutkar, Emily Lawler, Rana Besada, Michael T Hemann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. MultiplexedbioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Eleanor R C FiedlerThe Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA.
Arjun BhutkarThe Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA.
Emily LawlerThe Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA.
Rana BesadaThe Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA.
Michael T HemannThe Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA.
Massachusetts Institute of Technology · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
NCI NIH HHS P30 CA014051NIGMS NIH HHS T32 GM007287
6 · The paper itself

Abstract

Despite the addition of tyrosine kinase inhibitors (TKIs) to the treatment of patients with

Indexed as

Neoplasms, ExperimentalPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma1-Alkyl-2-acetylglycerophosphocholine EsteraseAnimalsDasatinibFusion Proteins, bcr-ablMiceMice, KnockoutProtein Kinase Inhibitors1-Alkyl-2-acetylglycerophosphocholine EsteraseDasatinibFusion Proteins, bcr-ablPAFAH1b3 protein, mouseProtein Kinase Inhibitors

Identifiers

PMID29853524
PMCPMC5998924
OpenAlexW2805294475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.